How does IZTC's PB Ratio compare to its peers?

IZTC has negative equity and a Price-To-Book Ratio (-33.4x) compared to the peer average (15.3x).

How does IZTC's PB Ratio compare vs other companies in the US Biotechs Industry?

IZTC has negative equity and a Price-To-Book Ratio (-33.4x) compared to the US Biotechs industry average (1.8x).

What is IZTC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate IZTC's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of IZTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate IZTC's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

IZTC Stock Overview

Operates as a synthetic biochemical company in the United States. More details

IZTC fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Revenue has declined by 100.7% over the past year

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($-700)

Negative shareholders equity

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Invizyne Technologies, Inc. Competitors

Actuate Therapeutics

NasdaqGM:ACTU

US$155.5m

Nkarta

NasdaqGS:NKTX

US$175.7m

Zura Bio

NasdaqCM:ZURA

US$163.2m

Greenwich LifeSciences

NasdaqCM:GLSI

US$147.6m

Price History & Performance

Summary of share price highs, lows and changes for Invizyne Technologies
Historical stock prices
Current Share Price	US$14.81
52 Week High	US$23.00
52 Week Low	US$8.50
Beta	0
1 Month Change	20.70%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	71.21%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	IZTC	US Biotechs	US Market
7D	-27.8%	-1.9%	-2.8%
1Y	n/a	-5.7%	24.1%

Return vs Industry: Insufficient data to determine how IZTC performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how IZTC performed against the US Market.

Price Volatility

Is IZTC's price volatile compared to industry and market?
IZTC volatility
IZTC Average Weekly Movement	19.0%
Biotechs Industry Average Movement	10.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	18.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IZTC's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IZTC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	31	Michael Heltzen	www.invizyne.com

Invizyne Technologies, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion.

Invizyne Technologies, Inc. Fundamentals Summary

How do Invizyne Technologies's earnings and revenue compare to its market cap?
IZTC fundamental statistics
Market cap	US$134.10m
Earnings (TTM)	-US$5.12m
Revenue (TTM)	n/a

9,999x

P/S Ratio

-23.5x

P/E Ratio

Is IZTC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IZTC income statement (TTM)
Revenue	-US$700.00
Cost of Revenue	US$0
Gross Profit	-US$700.00
Other Expenses	US$5.12m
Earnings	-US$5.12m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.63
Gross Margin	100.00%
Net Profit Margin	731,989.29%
Debt/Equity Ratio	-122.6%

How did IZTC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 04:39
End of Day Share Price	2025/01/02 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Invizyne Technologies, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution